Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 8/20 | 0.48 |
| ▸ | PROKR1 | Q8TCW9 | 8/20 | 0.48 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5020187 | 0.78 | FPR2 (0.49) | FPR2PROKR1MMP12MMP13MMP1 | |
| SCHEMBL4789741 | 0.74 | DRD2 (0.43) | KMT2A | |
| SCHEMBL4752293 | 0.71 | FPR2 (0.57) | FPR2PROKR1MMP12MMP13EPHX2 | |
| SCHEMBL8777604 | 0.68 | FPR2 (0.48) | FPR2PROKR1MMP12MMP13EPHX2 | |
| SCHEMBL4752287 | 0.68 | FPR2 (0.48) | FPR2PROKR1MMP12MMP13MMP1 | |
| SCHEMBL5020189 | 0.67 | FPR2 (0.52) | FPR2PROKR1 | |
| SCHEMBL3088605 | 0.66 | CYP3A4 (0.48) | MAPTSMN1; SMN2CYP2C9MEN1LMNA | |
| SCHEMBL4753032 | 0.66 | FPR2 (0.47) | FPR2PROKR1MMP12MMP13EPHX2 | |
| SCHEMBL14581927 | 0.66 | FPR2 (0.45) | FPR2PROKR1MMP12MMP13MAPT | |
| SCHEMBL8096415 | 0.66 | MMP12 (0.45) | FPR2PROKR1MMP12MMP13MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008147764-A1 | MMP INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. (US) | 2008-12-04 | — | — | WO | claimed |
| US-20140121248-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| WO-2008147764-A1 | MMP INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121248-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | FPR2 2862/4885PROKR1 3666/4885MMP12 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.